Meeting
2018 ASCO Annual Meeting
Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).
Authors
Andreas Nicholas Saltos
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Andreas Nicholas Saltos , Tawee Tanvetyanon , Charles C. Williams , Eric B. Haura , Ben C. Creelan , Scott Joseph Antonia , Nishan Tchekmedyian , Kristen Goas , Trevor Mamplata , Ram Thapa , Dung-Tsa Chen , Amer A. Beg , Jhanelle Elaine Gray
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02638090
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9046)
DOI
10.1200/JCO.2018.36.15_suppl.9046
Abstract #
9046
Poster Bd #
369
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results.
First Author: Andreas Nicholas Saltos
Poster
2020 ASCO Virtual Scientific Program
Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).
First Author: Andreas Nicholas Saltos
Poster
2019 ASCO Annual Meeting
Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Updated results.
First Author: Andreas Nicholas Saltos
Poster
2023 ASCO Annual Meeting
A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.
First Author: Montaser F. Shaheen